Lilly hopes volume can make up for late migraine entry
In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
No price relief in 2019, Pfizer confirms
The biggest of big pharma companies has added to the downbeat tone for the year. Drug makers need to keep thinking on pricing.
Could big biotech succumb to the urge to merge?
With growth stalling at some of the industry's biggest biotechs is it time to take a leaf out of big pharma's M&A playbook?
